Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India

5Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The therapeutic landscape in advanced gastrointestinal stromal tumor has evolved. Avapritinib and ripretinib have now been approved by the US FDA for platelet-derived growth factor alpha D842V-mutant and refractory gastrointestinal stromal tumor patients, respectively. Herewe report five patients who have been on avapritinib under an expanded access program. Response assessment was available for four patients - a partial response in two patients and stable disease in one, while one patient had progressive disease. Though preliminary results of the VOYAGER trial have shown less activity of avapritinib and no significant difference in progression-free survival when compared with regorafenib, avapritinib may show some clinical benefit in a subset of patients refractory to approved therapies. We share our experience of five cases, with clinical benefit in three. We believe avapritinib should be further evaluated in clinical trials.

Cite

CITATION STYLE

APA

Verma, S., Reddy, R., Chandrashekhara, S. H., Shamim, S. A., Tripathy, S., & Rastogi, S. (2021). Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India. Future Science OA, 7(4). https://doi.org/10.2144/FSOA-2020-0178

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free